OP-EDS

How to ensure sustainability and wider stakeholder acceptability in NLEM revisions

Dec-2022

Nilaya Varma, CEO and Managing Director, Primus Partners shares his thoughts on the 4th revision of the National List of Essential Medicines, in particular releasing frequent revisions to the list as well as providing greater financial incentives to pharma companies.

Img

EXPLORE MORE PRIMUS RESEARCH

Img
Newsletter & Policy Updates

Trade and Investment Bulletin | March 2023

Mar-2023
Img
Newsletter & Policy Updates

Monthly Policy Note | March 2023

Mar-2023